Pharmacotherapy of allergic rhinitis: a pharmaco‐economic approach
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
This article reports on a systematic literature review of the costs of allergic rhinitis (AR), the economic value of pharmacotherapy of AR, and the factors affecting costs and economic value of pharmacotherapy. Included studies had carried out a cost‐of‐illness analysis, cost analysis, cost‐effectiveness, cost‐utility or cost‐benefit analysis. Allergic rhinitis imposes a substantial economic burden on society, with indirect costs of productivity loss being larger than the direct healthcare costs. Cost estimates were biased because of difficulties of diagnosis; exclusion of patients who do not seek healthcare; exclusion of over‐the‐counter medication; difficulties in estimating productivity loss. There is limited evidence on costs of seasonal/perennial and intermittent/persistent AR. Little is known of the economic value of pharmacotherapy of AR, although levocetirizine appears to be cost‐effective as compared with placebo. Economic evaluations suffered limitations from small sample sizes, short trial duration, lack of standardized effectiveness measure, restricted scope of costs. Finally, the economic value of pharmacotherapy of AR is influenced by the perspective of the economic evaluation, relative effectiveness and costs of available drugs, patient compliance with treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*
Bousquet, J., Khaltaev, N., Cruz, A. A., Denburg, J., Fokkens, W. J., Togias, A., Zuberbier, T., Baena‐Cagnani, C. E., Canonica, G. W., Van Weel, C., et al. (2008) · Allergy · doi:10.1111/j.1398-9995.2007.01620.x · Cited by 4,729
Allergic Rhinitis and Its Impact on Asthma
Bousquet, J., van Cauwenberge, P., & Khaltaev, N. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.118891 · Cited by 3,588
Weiner, J. M., Abramson, M. J., & Puy, R. M. (1998) · BMJ · doi:10.1136/bmj.317.7173.1624 · Cited by 527 · cited 2×
“The literature has shown that intranasal glucocorticosteroids are the most effective drugs in adults and children (6, 23).”
BackgroundThe burden of allergic rhinitis
Nathan, R. A. (2007) · Allergy and Asthma Proceedings · doi:10.2500/aap.2007.28.2934 · Cited by 472
Epidemiology of seasonal and perennial rhinitis: clinical presentation and medical history.
Sibbald, B., & Rink, E. (1991) · Thorax · doi:10.1136/thx.46.12.895 · Cited by 333 · cited 1×
“Allergic rhinitis symptoms include rhinorrhea, nasal obstruction, nasal itching and sneezing (3).”
BackgroundLamb, C. E., Ratner, P. H., Johnson, C. E., Ambegaonkar, A. J., Joshi, A. V., Day, D., Sampson, N., & Eng, B. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x112552 · Cited by 288 · cited 2×
“A comparative analysis found that the indirect costs per employee per year amounted to US$593 for AR, $518 for high stress, $277 for migraine, $273 for depression, $269 for arthritis/rheumatism, $248 for anxiety disorder, $181 for respiratory infections, $105 for hypertension or high blood pressure, $95 for diabetes,…”
BackgroundEconomic impact and quality-of-life burden of allergic rhinitis
Schoenwetter, W. F., Dupclay, L., Appajosyula, S., Botteman, M. F., & Pashos, C. L. (2004) · Current Medical Research and Opinion · doi:10.1185/030079903125003053 · Cited by 256
The Economic Burden of Allergic Rhinitis: A Critical Evaluation of the Literature
Reed, S. D., Lee, T. A., & McCrory, D. C. (2004) · PharmacoEconomics · doi:10.2165/00019053-200422060-00002 · Cited by 222
Bachert, C., Bousquet, J., Canonica, G. W., Durham, S. R., Klimek, L., Mullol, J., Van Cauwenberge, P. B., & Van Hammée, G. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.05.070 · Cited by 215 · cited 13×
“A cost-consequence analysis compared treatment with levocetirizine 5 mg or with placebo for patients suffering from PER sensitized to both grass pollen and house dust mite (45).”
BackgroundMethodInfluentialThe work impact of asthma and rhinitis
Blanc, P. D., Trupin, L., Eisner, M., Earnest, G., P Katz, P., Israel, L., & Yelin, E. H. (2001) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00349-8 · Cited by 188
Cited by
Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology
Pirazzini, M., Rossetto, O., Eleopra, R., & Montecucco, C. (2017) · Pharmacological Reviews · doi:10.1124/pr.116.012658 · Cited by 768
Chinese Society of Allergy Guidelines for Diagnosis and Treatment of Allergic Rhinitis
Cheng, L., Chen, J., Fu, Q., He, S., Li, H., Liu, Z., Tan, G., Tao, Z., Wang, D., Wen, W., et al. (2018) · Allergy, Asthma & Immunology Research · doi:10.4168/aair.2018.10.4.300 · Cited by 361
Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders
Hallett, M., Albanese, A., Dressler, D., Segal, K. R., Simpson, D. M., Truong, D., & Jankovic, J. (2013) · Toxicon · doi:10.1016/j.toxicon.2012.12.004 · Cited by 272
Allergic rhinitis and the common cold – high cost to society
Hellgren, J., Cervin, A., Nordling, S., Bergman, A., & Cardell, L. O. (2010) · Allergy · doi:10.1111/j.1398-9995.2009.02269.x · Cited by 183
Caballer, B. D. L. H., Rodríguez, M., Fraj, J., Cerecedo, I., Antolín-Amérigo, D., & Colas, C. (2012) · American Journal of Rhinology & Allergy · doi:10.2500/ajra.2012.26.3799 · Cited by 106
Metadata
- Authors
- Simoens, S., & Laekeman, G.
- Venue
- Allergy
- Publisher
- Wiley
- Published
- 2008-12-23
- Volume
- 64
- Issue
- 1
- Pages
- 85-95
- ISSN
- 0105-4538 (ISSN-L)
- 1398-9995
- OpenAlex
- W2015123030
- Cited by
- 42
- References
- 11
- FWCI
- 2.58
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacotherapy of allergic rhinitis: a pharmaco‐economic approach. https://app.cochat.ai/papers/10.1111/j.1398-9995.2008.01909.x
- The paper
- Simoens, S., & Laekeman, G. (2009). Pharmacotherapy of allergic rhinitis: a pharmaco‐economic approach. Allergy. https://doi.org/10.1111/j.1398-9995.2008.01909.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.